Skip to main content
Premium Trial:

Request an Annual Quote

Alan Krensky

Premium
The US National Institutes of Health has appointed Alan Krensky to be its first deputy director for the Office of Portfolio Analysis and Strategic Initiatives, or OPASI. Krensky, who will start the job on July 8, will oversee the Office’s position as an “incubator space to address critical research efforts in cross-cutting areas of NIH priorities,” NIH Elias Zerhouni said in a statement this week.
 
OPASI was created to “identify important areas of emerging scientific opportunities or rising public health challenges, and to help accelerate investments in these areas to make sure new ideas have a chance to develop,” according to the NIH. 
 
Krensky comes to OPASI from StanfordUniversity, where he worked at the school of medicine as professor of pediatrics. He was also chief of the Division of Immunology and Transplantation Biology, associate chair for research in the Department of Pediatrics, and associate dean for Children's Health. He has an MD from the University of Pennsylvania.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.